SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $681 | -37.2% | 24,688 | -31.6% | 0.03% | -36.5% |
| Q2 2023 | $1,085 | -17.2% | 36,088 | -0.3% | 0.05% | -22.4% |
| Q1 2023 | $1,311 | -8.6% | 36,188 | -10.0% | 0.07% | -14.1% |
| Q4 2022 | $1,434 | -99.9% | 40,188 | 0.0% | 0.08% | +2.6% |
| Q3 2022 | $1,360,000 | +17.0% | 40,188 | 0.0% | 0.08% | +24.6% |
| Q2 2022 | $1,162,000 | -10.5% | 40,188 | 0.0% | 0.06% | +5.2% |
| Q1 2022 | $1,299,000 | +10.8% | 40,188 | 0.0% | 0.06% | +9.4% |
| Q4 2021 | $1,172,000 | -37.2% | 40,188 | -42.6% | 0.05% | -37.6% |
| Q3 2021 | $1,867,000 | -16.1% | 69,988 | -3.2% | 0.08% | -14.1% |
| Q2 2021 | $2,226,000 | +17.7% | 72,288 | 0.0% | 0.10% | +12.5% |
| Q1 2021 | $1,892,000 | +4.0% | 72,288 | 0.0% | 0.09% | -2.2% |
| Q4 2020 | $1,819,000 | +22.2% | 72,288 | +1.3% | 0.09% | -11.8% |
| Q3 2020 | $1,488,000 | -12.0% | 71,388 | +0.3% | 0.10% | +5.2% |
| Q2 2020 | $1,691,000 | +32.9% | 71,188 | +0.7% | 0.10% | +12.8% |
| Q1 2020 | $1,272,000 | -24.2% | 70,688 | 0.0% | 0.09% | -5.5% |
| Q4 2019 | $1,677,000 | -65.1% | 70,688 | -59.6% | 0.09% | -61.3% |
| Q3 2019 | $4,806,000 | -12.0% | 174,888 | +5.9% | 0.24% | -10.6% |
| Q2 2019 | $5,463,000 | -8.6% | 165,088 | -3.2% | 0.26% | -7.7% |
| Q1 2019 | $5,977,000 | +5.2% | 170,588 | -0.3% | 0.28% | -5.0% |
| Q4 2018 | $5,684,000 | -34.1% | 171,088 | -0.1% | 0.30% | -17.4% |
| Q3 2018 | $8,619,000 | -15.9% | 171,188 | 0.0% | 0.36% | -23.7% |
| Q2 2018 | $10,246,000 | +28.9% | 171,188 | -1.4% | 0.48% | +22.7% |
| Q1 2018 | $7,948,000 | +13.6% | 173,535 | -1.1% | 0.39% | +20.5% |
| Q4 2017 | $6,995,000 | -0.4% | 175,535 | -0.1% | 0.32% | -12.0% |
| Q3 2017 | $7,025,000 | -7.2% | 175,635 | 0.0% | 0.37% | -10.9% |
| Q2 2017 | $7,570,000 | +33.9% | 175,635 | -2.8% | 0.41% | +36.1% |
| Q1 2017 | $5,654,000 | +17.4% | 180,635 | -5.2% | 0.30% | +15.3% |
| Q4 2016 | $4,814,000 | +1.0% | 190,635 | -1.0% | 0.26% | -1.5% |
| Q3 2016 | $4,764,000 | +21.4% | 192,635 | 0.0% | 0.27% | +14.7% |
| Q2 2016 | $3,924,000 | – | 192,635 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |